Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
1.2B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.3B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Monte Rosa Therapeutics Inc
Glance View
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-06-24. The company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. The company focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Monte Rosa Therapeutics Inc is 11.5%, which is above its 3-year median of -2 263.3%.
Over the last 2 years, Monte Rosa Therapeutics Inc’s Net Margin has increased from -12 714.3% to 11.5%. During this period, it reached a low of -12 714.3% on Mar 31, 2024 and a high of 13.6% on Jun 30, 2025.
